Pelacarsen

Novartis · TQJ230 · ISIS 681257

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
4 active
10 in total · 6 in the EU
Targets
 

What this is

How it works
Lp(a) antisense oligonucleotide
How it’s given
“Pelacarsen will be provided as solution for injection in prefilled syringe 80 mg for subcutaneous injection.”In the company’s words, NCT06813911 on ClinicalTrials.gov
Tested for
Atherosclerotic Cardiovascular Disease (ASCVD), Cardiovascular Disease and Lipoprotein(a), Atherosclerotic Cardiovascular Disease, Aortic Stenosis
Main trialPhase 3
“The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on background inclisiran treatment for elevated low-density lipoprotein cholesterol (LDL-C). Study has been terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not meet its primary endpoint”In the company’s words, NCT06813911 on ClinicalTrials.gov
Other names
TQJ230 · ISIS 681257

Other drugs for Atherosclerotic Cardiovascular Disease (ASCVD)

All 29 drugs for Atherosclerotic Cardiovascular Disease (ASCVD)

Coming up4

Changes2

Last 90 days

Trials10

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 3 Feb 2028 Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
Phase 3Active, not recruiting 9 Jan 2030 An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Phase 3Active, not recruiting 8 Dec 2030 Pelacarsen Roll-over Extension Program
Phase 2Recruiting 12 Mar 2030 A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
Phase 3Completed 28 Jan 2025 A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Rate of Weekly Lipoprotein Apheresis Sessions in Patients With Hyperlipoproteinemia(a) and Established Cardiovascular Disease in Germany
Phase 3Completed 25 Mar 2026 Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD
Phase 3Completed 16 Jul 2026 Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
Phase 3Terminated 15 Oct 2026 An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Phase 3Withdrawn 22 Jan 2029 Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
Phase 1Completed 19 Oct 2022 Study to Assess the Pharmacokinetics of Pelacarsen (TQJ230) in Participants With Mild Hepatic Impairment Compared to Matched Healthy Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Pelacarsen

Following is part of Solo: you see every change to Pelacarsen the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in